메뉴 건너뛰기




Volumn 12, Issue 5, 2010, Pages 408-416

Emerging pharmacologic therapies for irritable bowel syndrome

Author keywords

5 HT3 antagonist; 5 HT4 agonist; Anti inflammatory; Benzodiazepine receptor modulator; Bile acid; Constipation; Diarrhea; Peripheral visceral analgesic; Secretagogue; Treatment

Indexed keywords

ALOSETRON; ASIMADOLINE; ATI 7505; CHENODEOXYCHOLIC ACID; COLESEVELAM; CROFELEMER; CROMOGLYCATE DISODIUM; DEXLOXIGLUMIDE; DEXTOFISOPAM; EZLOZIPANT; GUANYLATE CYCLASE ACTIVATOR; GW 876008; KETOTIFEN; LAXATIVE; LINACLOTIDE; LUBIPROSTONE; MESALAZINE; NEPADUTANT; PLACEBO; PREDNISONE; PRUCALOPRIDE; RAMOSETRON; SEROTONIN 4 AGONIST; SOLABEGRON; TACHYKININ RECEPTOR ANTAGONIST; TALNETANT; TD 5108; TEGASEROD; UNCLASSIFIED DRUG; VELUSETRAG;

EID: 77958180631     PISSN: 15228037     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11894-010-0124-1     Document Type: Review
Times cited : (19)

References (45)
  • 1
    • 2442581507 scopus 로고    scopus 로고
    • Treating irritable bowel syndrome: Overview, perspective and future therapies
    • DOI 10.1038/sj.bjp.0705741
    • M Camilleri 2004 Treating irritable bowel syndrome: overview, perspective and future therapies Br J Pharmacol 141 1237 1248 1:CAS:528: DC%2BD2cXktFCgtLk%3D 10.1038/sj.bjp.0705741 15037521 (Pubitemid 38638813)
    • (2004) British Journal of Pharmacology , vol.141 , Issue.8 , pp. 1237-1248
    • Camilleri, M.1
  • 2
    • 33846347644 scopus 로고    scopus 로고
    • The Serotonin Signaling System: From Basic Understanding To Drug Development for Functional GI Disorders
    • DOI 10.1053/j.gastro.2006.11.002, PII S001650850602436X
    • MD Gershon J Tack 2007 The serotonin signaling system: from basic understanding to drug development for functional GI disorders Gastroenterology 132 397 414 1:CAS:528:DC%2BD2sXit1aqt78%3D 10.1053/j.gastro.2006.11.002 17241888 (Pubitemid 46127672)
    • (2007) Gastroenterology , vol.132 , Issue.1 , pp. 397-414
    • Gershon, M.D.1    Tack, J.2
  • 3
    • 70350567652 scopus 로고    scopus 로고
    • Current and novel therapeutic options for irritable bowel syndrome management
    • 1:STN:280:DC%2BD1Mjktl2gtA%3D%3D 10.1016/j.dld.2009.07.009 19665953
    • M Camilleri V Andresen 2009 Current and novel therapeutic options for irritable bowel syndrome management Dig Liver Dis 41 854 862 1:STN:280:DC%2BD1Mjktl2gtA%3D%3D 10.1016/j.dld.2009.07.009 19665953
    • (2009) Dig Liver Dis , vol.41 , pp. 854-862
    • Camilleri, M.1    Andresen, V.2
  • 4
    • 71549121350 scopus 로고    scopus 로고
    • Review article: New receptor targets for medical therapy in irritable bowel syndrome
    • 1:CAS:528:DC%2BC3cXnvFCltg%3D%3D 10.1111/j.1365-2036.2009.04153.x 19785622
    • M Camilleri 2010 Review article: new receptor targets for medical therapy in irritable bowel syndrome Aliment Pharmacol Ther 31 35 46 1:CAS:528:DC%2BC3cXnvFCltg%3D%3D 10.1111/j.1365-2036.2009.04153.x 19785622
    • (2010) Aliment Pharmacol Ther , vol.31 , pp. 35-46
    • Camilleri, M.1
  • 5
    • 44349130441 scopus 로고    scopus 로고
    • A placebo-controlled trial of prucalopride for severe chronic constipation
    • DOI 10.1056/NEJMoa0800670
    • M Camilleri R Kerstens A Rykx, et al. 2008 A placebo-controlled trial of prucalopride for severe chronic constipation N Engl J Med 358 2344 2354 1:CAS:528:DC%2BD1cXmsVKgsb0%3D 10.1056/NEJMoa0800670 18509121 This article describes the first pivotal phase 3 trial demonstrating that about 30% of patients with constipation achieve three or more SCBMs per week on prucalopride, compared to 12% on placebo (Pubitemid 351749158)
    • (2008) New England Journal of Medicine , vol.358 , Issue.22 , pp. 2344-2354
    • Camilleri, M.1    Kerstens, R.2    Rykx, A.3    Vandeplassche, L.4
  • 6
    • 58149084950 scopus 로고    scopus 로고
    • Clinical trial: The efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation-a 12-week, randomized, double-blind, placebo-controlled study
    • 1:STN:280:DC%2BD1M%2FlvFajsQ%3D%3D 10.1111/j.1365-2036.2008.03884.x 19035970 This article describes one of the three pivotal phase 3 trials reporting on the efficacy and tolerability of prucalopride in patients with severe constipation
    • EM Quigley L Vandeplassche R Kerstens, et al. 2009 Clinical trial: the efficacy, impact on quality of life, and safety and tolerability of prucalopride in severe chronic constipation-a 12-week, randomized, double-blind, placebo-controlled study Aliment Pharmacol Ther 29 315 328 1:STN:280: DC%2BD1M%2FlvFajsQ%3D%3D 10.1111/j.1365-2036.2008.03884.x 19035970 This article describes one of the three pivotal phase 3 trials reporting on the efficacy and tolerability of prucalopride in patients with severe constipation
    • (2009) Aliment Pharmacol Ther , vol.29 , pp. 315-328
    • Quigley, E.M.1    Vandeplassche, L.2    Kerstens, R.3
  • 7
    • 61649119045 scopus 로고    scopus 로고
    • Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives
    • 1:CAS:528:DC%2BD1MXjsFGgt7o%3D 10.1136/gut.2008.162404 18987031 This article describes one of the three pivotal phase 3 trials showing that prucalopride improves bowel function, associated symptoms, and satisfaction in chronically constipated patients
    • J Tack M van Outryve G Beyens, et al. 2009 Prucalopride (Resolor) in the treatment of severe chronic constipation in patients dissatisfied with laxatives Gut 58 357 365 1:CAS:528:DC%2BD1MXjsFGgt7o%3D 10.1136/gut.2008.162404 18987031 This article describes one of the three pivotal phase 3 trials showing that prucalopride improves bowel function, associated symptoms, and satisfaction in chronically constipated patients
    • (2009) Gut , vol.58 , pp. 357-365
    • Tack, J.1    Van Outryve, M.2    Beyens, G.3
  • 8
    • 0035121508 scopus 로고    scopus 로고
    • Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder
    • 1:CAS:528:DC%2BD3MXhtlKltL4%3D 10.1053/gast.2001.21166 11159875
    • EP Bouras M Camilleri DD Burton, et al. 2001 Prucalopride accelerates gastrointestinal and colonic transit in patients with constipation without a rectal evacuation disorder Gastroenterology 120 354 360 1:CAS:528: DC%2BD3MXhtlKltL4%3D 10.1053/gast.2001.21166 11159875
    • (2001) Gastroenterology , vol.120 , pp. 354-360
    • Bouras, E.P.1    Camilleri, M.2    Burton, D.D.3
  • 10
    • 0036024222 scopus 로고    scopus 로고
    • Prucalopride, a systemic enterokinetic, for the treatment of constipation
    • 1:CAS:528:DC%2BD38XntVCjs78%3D 10.1046/j.1365-2036.2002.01272.x 12144586
    • AV Emmanuel AJ Roy TJ Nicholls, et al. 2002 Prucalopride, a systemic enterokinetic, for the treatment of constipation Aliment Pharmacol Ther 16 1347 1356 1:CAS:528:DC%2BD38XntVCjs78%3D 10.1046/j.1365-2036.2002.01272.x 12144586
    • (2002) Aliment Pharmacol Ther , vol.16 , pp. 1347-1356
    • Emmanuel, A.V.1    Roy, A.J.2    Nicholls, T.J.3
  • 11
    • 0037540068 scopus 로고    scopus 로고
    • Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief: Results of a double-blind, placebo-controlled clinical trial
    • DOI 10.1159/000070202
    • G Coremans R Kerstens M De Pauw, et al. 2003 Prucalopride is effective in patients with severe chronic constipation in whom laxatives fail to provide adequate relief. Results of a double-blind, placebo-controlled clinical trial Digestion 67 82 89 1:CAS:528:DC%2BD3sXjsleitL4%3D 10.1159/000070202 12743445 (Pubitemid 36570307)
    • (2003) Digestion , vol.67 , Issue.1-2 , pp. 82-89
    • Coremans, G.1    Kerstens, R.2    De Pauw, M.3    Stevens, M.4
  • 12
    • 33845656047 scopus 로고    scopus 로고
    • 4 receptor agonist, ATI-7505, in humans
    • DOI 10.1111/j.1365-2982.2006.00865.x
    • M Camilleri MI Vazquez-Roque D Burton, et al. 2007 Pharmacodynamic effects of a novel prokinetic 5-HT receptor agonist, ATI-7505, in humans Neurogastroenterol Motil 19 30 38 1:CAS:528:DC%2BD2sXhtFOqu7bP 10.1111/j.1365-2982.2006.00865.x 17187586 This phase 2 trial demonstrated that ATI-7505 accelerates overall colonic transit, and tends to accelerate gastric emptying and loosen stool consistency in healthy subjects (Pubitemid 44952776)
    • (2007) Neurogastroenterology and Motility , vol.19 , Issue.1 , pp. 30-38
    • Camilleri, M.1    Vazquez-Roque, M.I.2    Burton, D.3    Ford, T.4    McKinzie, S.5    Zinsmeister, A.R.6    Druzgala, P.7
  • 13
    • 10744221896 scopus 로고    scopus 로고
    • Colonoscopy: Virtual, Optical, or Chromoscopic?
    • DOI 10.1053/j.gastro.2004.01.030
    • D Dennis M Palme I Irwin, et al. 2004 ATI-7505 is a novel, selective 5HT(4) receptor agonist that causes gastrointestinal prokinetic activity in dog Gastroenterology 126 A641 10.1053/j.gastro.2004.01.030 (Pubitemid 38298309)
    • (2004) Gastroenterology , vol.126 , Issue.3 , pp. 641
    • Sandler, R.S.1
  • 14
    • 72449143707 scopus 로고    scopus 로고
    • Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation
    • 1:CAS:528:DC%2BC3cXhtlOhu7k%3D 19691492 This phase 2 trial demonstrated that velusetrag (TD-5108) accelerates intestinal and colonic transit after single dosing and accelerates gastric emptying after multiple dosing in healthy subjects and patients with constipation
    • ML Manini M Camilleri M Goldberg, et al. 2010 Effects of Velusetrag (TD-5108) on gastrointestinal transit and bowel function in health and pharmacokinetics in health and constipation Neurogastroenterol Motil 22 42 49 1:CAS:528:DC%2BC3cXhtlOhu7k%3D 19691492 This phase 2 trial demonstrated that velusetrag (TD-5108) accelerates intestinal and colonic transit after single dosing and accelerates gastric emptying after multiple dosing in healthy subjects and patients with constipation
    • (2010) Neurogastroenterol Motil , vol.22 , pp. 42-49
    • Manini, M.L.1    Camilleri, M.2    Goldberg, M.3
  • 15
    • 70350566903 scopus 로고    scopus 로고
    • 4 agonist, is consistently better than placebo regardless of response definition in patients with chronic constipation
    • 4 agonist, is consistently better than placebo regardless of response definition in patients with chronic constipation Gastroenterology 134 A545
    • (2008) Gastroenterology , vol.134 , pp. 545
    • Goldberg, M.R.1    Li, Y.P.2    Pitzer, K.3
  • 16
    • 72449201670 scopus 로고    scopus 로고
    • 4 agonist with high intrinsic activity, shows immediate and sustained prokinetic activity in healthy subjects
    • 4 agonist with high intrinsic activity, shows immediate and sustained prokinetic activity in healthy subjects Gastroenterology 132 A60
    • (2007) Gastroenterology , vol.132 , pp. 60
    • Goldberg, M.R.1    Wong, S.L.2    Ganju, J.3
  • 17
    • 33847365318 scopus 로고    scopus 로고
    • Pharmacological profile of ramosetron, a novel therapeutic agent for IBS
    • DOI 10.1007/s10787-006-1537-1
    • T Hirata T Funatsu Y Keto, et al. 2007 Pharmacological profile of ramosetron, a novel therapeutic agent for IBS Inflammopharmacol 15 5 9 1:CAS:528:DC%2BD2sXktFWgsbk%3D 10.1007/s10787-006-1537-1 (Pubitemid 46333875)
    • (2007) Inflammopharmacology , vol.15 , Issue.1 , pp. 5-9
    • Hirata, T.1    Funatsu, T.2    Keto, Y.3    Nakata, M.4    Sasamata, M.5
  • 18
    • 42249111897 scopus 로고    scopus 로고
    • 3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: A comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer
    • DOI 10.1111/j.1365-2982.2007.01069.x
    • T Hirata Y Keto M Nakata, et al. 2008 Effects of serotonin 5-HT3 receptor antagonists on stress-induced colonic hyperalgesia and diarrhoea in rats: a comparative study with opioid receptor agonists, a muscarinic receptor antagonist and a synthetic polymer Neurogastroenterol Motil 20 557 565 1:CAS:528:DC%2BD1cXmslKlurg%3D 10.1111/j.1365-2982.2007.01069.x 18221252 (Pubitemid 351548641)
    • (2008) Neurogastroenterology and Motility , vol.20 , Issue.5 , pp. 557-565
    • Hirata, T.1    Keto, Y.2    Nakata, M.3    Takeuchi, A.4    Funatsu, T.5    Akuzawa, S.6    Sasamata, M.7    Miyata, K.8
  • 19
    • 48049093262 scopus 로고    scopus 로고
    • A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome
    • 1:CAS:528:DC%2BD1cXhtVejtrfN 10.1159/000150632 18667823
    • K Matsueda S Harasawa M Hongo, et al. 2008 A phase II trial of the novel serotonin type 3 receptor antagonist ramosetron in Japanese male and female patients with diarrhea-predominant irritable bowel syndrome Digestion 77 225 235 1:CAS:528:DC%2BD1cXhtVejtrfN 10.1159/000150632 18667823
    • (2008) Digestion , vol.77 , pp. 225-235
    • Matsueda, K.1    Harasawa, S.2    Hongo, M.3
  • 20
    • 52149088774 scopus 로고    scopus 로고
    • A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome
    • 1:CAS:528:DC%2BD1cXhtFCiu77I 10.1080/00365520802240255 18618371 This phase 3 trial demonstrated that ramosetron hydrochloride is effective and well tolerated in the treatment of abdominal pain, discomfort, and bowel habit in patients with diarrhea-predominant irritable bowel syndrome
    • K Matsueda S Harasawa M Hongo, et al. 2008 A randomized, double-blind, placebo-controlled clinical trial of the effectiveness of the novel serotonin type 3 receptor antagonist ramosetron in both male and female Japanese patients with diarrhea-predominant irritable bowel syndrome Scand J Gastroenterol 43 1202 1211 1:CAS:528:DC%2BD1cXhtFCiu77I 10.1080/00365520802240255 18618371 This phase 3 trial demonstrated that ramosetron hydrochloride is effective and well tolerated in the treatment of abdominal pain, discomfort, and bowel habit in patients with diarrhea-predominant irritable bowel syndrome
    • (2008) Scand J Gastroenterol , vol.43 , pp. 1202-1211
    • Matsueda, K.1    Harasawa, S.2    Hongo, M.3
  • 21
    • 57649120166 scopus 로고    scopus 로고
    • Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients
    • 1:CAS:528:DC%2BD1MXjtVykt7s%3D 10.1159/000185719 19092244
    • AW Mangel P Chaturvedi 2008 Evaluation of crofelemer in the treatment of diarrhea-predominant irritable bowel syndrome patients Digestion 78 180 186 1:CAS:528:DC%2BD1MXjtVykt7s%3D 10.1159/000185719 19092244
    • (2008) Digestion , vol.78 , pp. 180-186
    • Mangel, A.W.1    Chaturvedi, P.2
  • 22
    • 33645812780 scopus 로고    scopus 로고
    • Effect of lubiprostone, a novel GI chloride channel activator, on isolated smooth muscle
    • R Ueno KJ Engelke H Osama 2005 Effect of lubiprostone, a novel GI chloride channel activator, on isolated smooth muscle Neurogastroenterol Motil 17 625
    • (2005) Neurogastroenterol Motil , vol.17 , pp. 625
    • Ueno, R.1    Engelke, K.J.2    Osama, H.3
  • 23
    • 33847009038 scopus 로고    scopus 로고
    • Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the ClC-2 chloride channel, lubiprostone
    • 1:CAS:528:DC%2BD2sXjt1GltL4%3D 10.1152/ajpgi.00183.2006 17053162
    • AJ Moeser PK Nighot KJ Engelke, et al. 2007 Recovery of mucosal barrier function in ischemic porcine ileum and colon is stimulated by a novel agonist of the ClC-2 chloride channel, lubiprostone Am J Physiol Gastrointest Liver Physiol 292 G647 G656 1:CAS:528:DC%2BD2sXjt1GltL4%3D 10.1152/ajpgi.00183.2006 17053162
    • (2007) Am J Physiol Gastrointest Liver Physiol , vol.292
    • Moeser, A.J.1    Nighot, P.K.2    Engelke, K.J.3
  • 24
    • 33645837674 scopus 로고    scopus 로고
    • Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers
    • 10.1152/ajpgi.00264.2005
    • M Camilleri AE Bharucha R Ueno, et al. 2006 Effect of a selective chloride channel activator, lubiprostone, on gastrointestinal transit, gastric sensory, and motor functions in healthy volunteers Am J Physiol Gastrointest Liver Physiol 290 942 947 10.1152/ajpgi.00264.2005
    • (2006) Am J Physiol Gastrointest Liver Physiol , vol.290 , pp. 942-947
    • Camilleri, M.1    Bharucha, A.E.2    Ueno, R.3
  • 25
    • 59449108998 scopus 로고    scopus 로고
    • Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor function in healthy subjects
    • 1:CAS:528:DC%2BD1MXitVaqt7c%3D 10.1152/ajpgi.90558.2008 19033530
    • S Sweetser IA Busciglio M Camilleri, et al. 2009 Effect of a chloride channel activator, lubiprostone, on colonic sensory and motor function in healthy subjects Am J Physiol Gastrointest Liver Physiol 296 G295 G301 1:CAS:528:DC%2BD1MXitVaqt7c%3D 10.1152/ajpgi.90558.2008 19033530
    • (2009) Am J Physiol Gastrointest Liver Physiol , vol.296
    • Sweetser, S.1    Busciglio, I.A.2    Camilleri, M.3
  • 26
    • 40949131857 scopus 로고    scopus 로고
    • Clinical trial: Phase 2 study of lubiprostone for irritable bowel syndrome with constipation
    • DOI 10.1111/j.1365-2036.2008.03629.x
    • JF Johanson DA Drossman R Panas, et al. 2008 Clinical trial: phase 2 study of lubiprostone for irritable bowel syndrome with constipation Aliment Pharmacol Ther 27 685 696 1:CAS:528:DC%2BD1cXls1Kjtbo%3D 10.1111/j.1365-2036. 2008.03629.x 18248656 (Pubitemid 351406304)
    • (2008) Alimentary Pharmacology and Therapeutics , vol.27 , Issue.8 , pp. 685-696
    • Johanson, J.F.1    Drossman, D.A.2    Panas, R.3    Wahle, A.4    Ueno, R.5
  • 28
    • 60749099506 scopus 로고    scopus 로고
    • Pilot study on the effect of linaclotide in patients with chronic constipation
    • 1:CAS:528:DC%2BD1MXht1Shug%3D%3D 10.1038/ajg.2008.59 19098860
    • JM Johnston CB Kurtz DA Drossman, et al. 2009 Pilot study on the effect of linaclotide in patients with chronic constipation Am J Gastroenterol 104 125 132 1:CAS:528:DC%2BD1MXht1Shug%3D%3D 10.1038/ajg.2008.59 19098860
    • (2009) Am J Gastroenterol , vol.104 , pp. 125-132
    • Johnston, J.M.1    Kurtz, C.B.2    Drossman, D.A.3
  • 29
    • 77249122338 scopus 로고    scopus 로고
    • Efficacy of linaclotide for patients with chronic constipation
    • 1:CAS:528:DC%2BC3cXksVCrsb8%3D 10.1053/j.gastro.2009.12.050 20045700 This article reports a phase 2b trial of efficacy of linaclotide therapy with few adverse events in patients with chronic constipation
    • AJ Lembo CB Kurtz JE Macdougall, et al. 2010 Efficacy of linaclotide for patients with chronic constipation Gastroenterology 138 886 895.e1 1:CAS:528:DC%2BC3cXksVCrsb8%3D 10.1053/j.gastro.2009.12.050 20045700 This article reports a phase 2b trial of efficacy of linaclotide therapy with few adverse events in patients with chronic constipation
    • (2010) Gastroenterology , vol.138
    • Lembo, A.J.1    Kurtz, C.B.2    MacDougall, J.E.3
  • 30
    • 75349109261 scopus 로고    scopus 로고
    • Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function
    • 1:CAS:528:DC%2BC3cXjs1Grt7Y%3D 10.1016/j.cgh.2009.10.020 19879973 Two randomized, double-blind, placebo-controlled studies showed that sodium chenodeoxycholate in health and colesevelam in diarrhea-predominant irritable bowel syndrome have opposite effects on colonic transit and fecal parameters
    • ST Odunsi-Shiyanbade M Camilleri S McKinzie, et al. 2010 Effects of chenodeoxycholate and a bile acid sequestrant, colesevelam, on intestinal transit and bowel function Clin Gastroenterol Hepatol 8 159 165 1:CAS:528:DC%2BC3cXjs1Grt7Y%3D 10.1016/j.cgh.2009.10.020 19879973 Two randomized, double-blind, placebo-controlled studies showed that sodium chenodeoxycholate in health and colesevelam in diarrhea-predominant irritable bowel syndrome have opposite effects on colonic transit and fecal parameters
    • (2010) Clin Gastroenterol Hepatol , vol.8 , pp. 159-165
    • Odunsi-Shiyanbade, S.T.1    Camilleri, M.2    McKinzie, S.3
  • 31
    • 77957745464 scopus 로고    scopus 로고
    • Dose-related effects of chenodeoxycholate on gastrointestinal and colonic transit and bowel function in female patients with constipation-predominant irritable bowel syndrome
    • A Rao ST Odunsi M Camilleri, et al. 2010 Dose-related effects of chenodeoxycholate on gastrointestinal and colonic transit and bowel function in female patients with constipation-predominant irritable bowel syndrome Gastroenterology 138 S224
    • (2010) Gastroenterology , vol.138 , pp. 224
    • Rao, A.1    Odunsi, S.T.2    Camilleri, M.3
  • 32
    • 35448957983 scopus 로고    scopus 로고
    • Systematic evaluation of the causes of chronic watery diarrhea with functional characteristics
    • DOI 10.1111/j.1572-0241.2007.01438.x
    • F Fernández-Bañares M Esteve A Salas, et al. 2007 Systematic evaluation of the causes of chronic watery diarrhea with functional characteristics Am J Gastroenterol 102 2520 2528 10.1111/j.1572-0241.2007.01438. x 17680846 This prospective study assessed the presence of gluten-sensitive enteropathy, bile acid malabsorption, and sugar malabsorption in consecutive patients with chronic watery diarrhea of obscure origin fulfilling Rome II criteria (Pubitemid 47631771)
    • (2007) American Journal of Gastroenterology , vol.102 , Issue.11 , pp. 2520-2528
    • Fernandez-Banares, F.1    Esteve, M.2    Salas, A.3    Alsina, M.4    Farre, C.5    Gonzalez, C.6    Buxeda, M.7    Forne, M.8    Rosinach, M.9    Espinos, J.C.10    Maria Viver, J.11
  • 33
    • 67650480494 scopus 로고    scopus 로고
    • Measurement of serum 7alpha-hydroxy-4-cholesten-3-one (or 7alphaC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry
    • 1:CAS:528:DC%2BD1MXpt1OltL8%3D 10.1111/j.1365-2982.2009.01288.x 19368662
    • M Camilleri A Nadeau WJ Tremaine, et al. 2009 Measurement of serum 7alpha-hydroxy-4-cholesten-3-one (or 7alphaC4), a surrogate test for bile acid malabsorption in health, ileal disease and irritable bowel syndrome using liquid chromatography-tandem mass spectrometry Neurogastroenterol Motil 21 734 739 1:CAS:528:DC%2BD1MXpt1OltL8%3D 10.1111/j.1365-2982.2009.01288.x 19368662
    • (2009) Neurogastroenterol Motil , vol.21 , pp. 734-739
    • Camilleri, M.1    Nadeau, A.2    Tremaine, W.J.3
  • 34
    • 0037781447 scopus 로고    scopus 로고
    • Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome
    • 10.1111/j.1572-0241.2003.07542.x 12873581
    • SP Dunlop D Jenkins RC Spiller 2003 Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome Am J Gastroenterol 98 1578 1583 10.1111/j.1572-0241.2003.07542.x 12873581
    • (2003) Am J Gastroenterol , vol.98 , pp. 1578-1583
    • Dunlop, S.P.1    Jenkins, D.2    Spiller, R.C.3
  • 36
    • 71549163969 scopus 로고    scopus 로고
    • Clinical benefit in IBS after disodium cromoglycate involves mast cell-medicated recovery of healthy-like innate immunity genes expression profile in the jejunal mucosa
    • B Lobo M Vicario C Martinez, et al. 2009 Clinical benefit in IBS after disodium cromoglycate involves mast cell-medicated recovery of healthy-like innate immunity genes expression profile in the jejunal mucosa Gastroenterology 136 Suppl 1 156
    • (2009) Gastroenterology , vol.136 , Issue.SUPPL. 1 , pp. 156
    • Lobo, B.1    Vicario, M.2    Martinez, C.3
  • 37
    • 84871962585 scopus 로고    scopus 로고
    • Treatment with the mast cell stabilizer ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in IBS patients
    • Vienna, Austria OP397
    • Klooker TK, Koopman KE, Heide S, et al.: Treatment with the mast cell stabilizer ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in IBS patients. Proceedings of the United European Gastroenterology Federation (UEGF) Meeting. Vienna, Austria; 2008:OP397.
    • (2008) Proceedings of the United European Gastroenterology Federation (UEGF) Meeting
    • Klooker, T.K.1    Koopman, K.E.2    Heide, S.3
  • 38
    • 67650523807 scopus 로고    scopus 로고
    • Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: A randomized controlled proof-of-concept study
    • 1:CAS:528:DC%2BD1MXhtVSnurzE 10.1111/j.1365-2036.2009.04041.x 19438846
    • R Corinaldesi V Stanghellini C Cremon, et al. 2009 Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof-of-concept study Aliment Pharmacol Ther 30 245 252 1:CAS:528:DC%2BD1MXhtVSnurzE 10.1111/j.1365-2036.2009.04041.x 19438846
    • (2009) Aliment Pharmacol Ther , vol.30 , pp. 245-252
    • Corinaldesi, R.1    Stanghellini, V.2    Cremon, C.3
  • 40
    • 0032924832 scopus 로고    scopus 로고
    • The κ agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome
    • DOI 10.1016/S0016-5085(99)70226-X
    • M Delvaux D Louvel E Lagier, et al. 1999 The kappa agonist fedotozine relieves hypersensitivity to colonic distention in patients with irritable bowel syndrome Gastroenterology 116 38 45 1:CAS:528:DyaK1MXlsl2gsg%3D%3D 10.1016/S0016-5085(99)70226-X 9869600 (Pubitemid 29013491)
    • (1999) Gastroenterology , vol.116 , Issue.1 , pp. 38-45
    • Delvaux, M.1    Louvel, D.2    Lagier, E.3    Scherrer, B.4    Abitbol, J.-L.5    Frexinos, J.6
  • 41
    • 0037378287 scopus 로고    scopus 로고
    • Effects of a κ-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans
    • S Delgado-Aros HJ Chial M Camilleri, et al. 2003 Effects of a κ-opioid agonist, asimadoline, on satiation and GI motor and sensory functions in humans Am J Physiol Gastrointest Liver Physiol 284 558 566
    • (2003) Am J Physiol Gastrointest Liver Physiol , vol.284 , pp. 558-566
    • Delgado-Aros, S.1    Chial, H.J.2    Camilleri, M.3
  • 42
    • 45549083888 scopus 로고    scopus 로고
    • Clinical trial: Asimadoline in the treatment of patients with irritable bowel syndrome
    • DOI 10.1111/j.1365-2036.2008.03730.x
    • AW Mangel JD Bornstein LR Hamm, et al. 2008 Clinical trial: asimadoline in the treatment of patients with irritable bowel syndrome Aliment Pharmacol Ther 28 239 249 1:CAS:528:DC%2BD1cXps1Gmt7k%3D 10.1111/j.1365-2036.2008.03730.x 18466359 (Pubitemid 351861967)
    • (2008) Alimentary Pharmacology and Therapeutics , vol.28 , Issue.2 , pp. 239-249
    • Mangel, A.W.1    Bornstein, J.D.2    Hamm, L.R.3    Buda, J.4    Wang, J.5    Irish, W.6    Urso, D.7
  • 43
    • 35548931920 scopus 로고    scopus 로고
    • Efficacy of On-Demand Asimadoline, a Peripheral κ-Opioid Agonist, in Females With Irritable Bowel Syndrome
    • DOI 10.1016/j.cgh.2007.07.011, PII S1542356507007148
    • LA Szarka M Camilleri D Burton, et al. 2007 Efficacy of on-demand asimadoline, a peripheral κ-opioid agonist, in females with irritable bowel syndrome Clin Gastroenterol Hepatol 5 1268 1275 1:CAS:528: DC%2BD2sXhsVektbzI 10.1016/j.cgh.2007.07.011 17900994 This randomized study compared the effect of the κ-opioid agonist, asimadoline, and placebo on episodes of abdominal pain in patients with IBS (Pubitemid 350019057)
    • (2007) Clinical Gastroenterology and Hepatology , vol.5 , Issue.11 , pp. 1268-1275
    • Szarka, L.A.1    Camilleri, M.2    Burton, D.3    Fox, J.C.4    McKinzie, S.5    Stanislav, T.6    Simonson, J.7    Sullivan, N.8    Zinsmeister, A.R.9
  • 44
    • 0030900827 scopus 로고    scopus 로고
    • Irritable bowel syndrome: A technical review for practice guideline development
    • DOI 10.1053/gast.1997.v112.agast972120
    • J Kanto L Kangas T Leppanen, et al. 1997 Tofizopam: a technical review for practice guideline development Gastroenterology 112 2120 2137 10.1053/gast.1997.v112.agast972120 (Pubitemid 27240803)
    • (1997) Gastroenterology , vol.112 , Issue.6 , pp. 2120-2137
    • Drossman, D.A.1    Whitehead, W.E.2    Camilleri, M.3
  • 45
    • 37149041916 scopus 로고    scopus 로고
    • Clinical trial: Dextofisopam in the treatment of patients with diarrhoea-predominant or alternating irritable bowel syndrome
    • DOI 10.1111/j.1365-2036.2007.03566.x
    • SM Leventer K Raudibaugh CL Frissora, et al. 2008 Clinical trial: dextofisopam in the treatment of patients with diarrhea-predominant or alternating irritable bowel syndrome Aliment Pharmacol Ther 27 197 206 1:CAS:528:DC%2BD1cXitVKrsbY%3D 10.1111/j.1365-2036.2007.03566.x 17973974 (Pubitemid 350256611)
    • (2008) Alimentary Pharmacology and Therapeutics , vol.27 , Issue.2 , pp. 197-206
    • Leventer, S.M.1    Raudibaugh, K.2    Frissora, C.L.3    Kassem, N.4    Keogh, J.C.5    Phillips, J.6    Mangel, A.W.7


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.